John Hornsby, MD
Hospitalist · Denver, CONPI 1396701728
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $681 and has fallen 87.2% since, to $87 in 2022. Among hospitalist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$148
- Tris Pharma Inc$146
- Novo Nordisk$102
- Lilly USA, LLC$80
- Johnson & Johnson$68
- Abbott$64
- plus $517 from 17 others
What the payments were for
- Food & beverage$1,124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $148 |
| Tris Pharma Inc | 3 | $146 |
| Novo Nordisk | 7 | $102 |
| Lilly USA, LLC | 6 | $80 |
| Johnson & Johnson | 4 | $68 |
| Abbott | 4 | $64 |
| Boehringer Ingelheim | 2 | $53 |
| Astellas Pharma US Inc | 3 | $49 |
| Pfizer | 3 | $44 |
| GSK | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $40 |
| Merck | 3 | $37 |
| Shire North American Group Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Amgen | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
$1,124 in reported general payments places this provider in the 95th percentile of 547 hospitalist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $103,223 |
| MounjaroTirzepatide | 60 | $75,648 |
| OzempicSemaglutide | 42 | $75,399 |
| XareltoRivaroxaban | 37 | $52,541 |
| JardianceEmpagliflozin | 26 | $34,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $29,812 |
| TrulicityDulaglutide | 14 | $20,439 |
| FarxigaDapagliflozin Propanediol | 25 | $20,178 |
| MyrbetriqMirabegron | 22 | $17,499 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $14,264 |
| Novolog FlexpenInsulin Aspart | 18 | $6,329 |
| Gabapentin | 261 | $3,465 |
| Levothyroxine Sodium | 324 | $3,419 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,912 |
| Atorvastatin Calcium | 340 | $2,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $103,22380 claims |
| Lilly USA, LLCMounjaro, Trulicity | $80 | $96,08674 claims |
| Novo NordiskOzempic | $102 | $75,39942 claims |
| Johnson & JohnsonXarelto | $68 | $52,54137 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $40 | $44,07655 claims |
| Boehringer IngelheimJardiance | $53 | $34,28726 claims |
| AstraZenecaFarxiga, Symbicort | $148 | $23,09037 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $17,49922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 hospitalist providers in Colorado.
Other hospitalist in Denver
- Neel GakharDenver$3K
- Kimberly Schatz MartinDenver$1K
- Joseph RamharackDenver$535
- Spencer PetersonDenver$521
- Jennifer GrayDenver$470
- Daniel LevyDenver$402
- Ryan FriedmanDenver$355
- Tejas PatilAurora$94K
- Janna Gelderman-MoffettLouisville$34K
- Michael SolaAurora$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.